Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug combination
Biotech
Sierra buys AstraZeneca cancer drug to pair with ex-Gilead asset
Sierra plans to start a phase 2 trial testing the BET inhibitor in combination with the JAK inhibitor it picked up from Gilead in 2018.
Nick Paul Taylor
Aug 5, 2021 4:05pm
New insight into a struggling AZ cancer drug could expand its use
May 17, 2019 10:27am
Bristol-Myers, Compugen ally to test checkpoint combinations
Oct 11, 2018 9:10am
Bristol-Myers posts early data on IDO1-checkpoint inhibitor combo
Nov 10, 2017 9:28am
Celgene bags Beigene PD-1 drug for $263M up front
Jul 6, 2017 4:22am
Incyte climbs on combo data for IDO inhibitor epacadostat
May 18, 2017 8:07am
